We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Eli Lilly and (LLY - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of LLY and the rest of the Medical group's stocks.
Eli Lilly and is a member of the Medical sector. This group includes 889 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. LLY is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for LLY's full-year earnings has moved 0.57% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, LLY has gained about 16.51% so far this year. Meanwhile, the Medical sector has returned an average of -1.32% on a year-to-date basis. As we can see, Eli Lilly and is performing better than its sector in the calendar year.
Breaking things down more, LLY is a member of the Large Cap Pharmaceuticals industry, which includes 15 individual companies and currently sits at #15 in the Zacks Industry Rank. On average, this group has lost an average of 0.27% so far this year, meaning that LLY is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track LLY. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Eli Lilly and (LLY - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of LLY and the rest of the Medical group's stocks.
Eli Lilly and is a member of the Medical sector. This group includes 889 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. LLY is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for LLY's full-year earnings has moved 0.57% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, LLY has gained about 16.51% so far this year. Meanwhile, the Medical sector has returned an average of -1.32% on a year-to-date basis. As we can see, Eli Lilly and is performing better than its sector in the calendar year.
Breaking things down more, LLY is a member of the Large Cap Pharmaceuticals industry, which includes 15 individual companies and currently sits at #15 in the Zacks Industry Rank. On average, this group has lost an average of 0.27% so far this year, meaning that LLY is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track LLY. The stock will be looking to continue its solid performance.